Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H8I3N2O4.Na |
Molecular Weight | 635.8954 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)NC1=C(I)C(C([O-])=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=ZEYOIOAKZLALAP-UHFFFAOYSA-M
InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1
DescriptionSources: http://www.drugbank.ca/drugs/DB00271Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00271
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=3198373
Curator's Comment: Diatrizoic acid was discovered in 1953 simultaneously and independently by Schering AG in Berlin and by Sterling-Winthrop in the USA.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Cystografin Approved UseRetrograde cystourethrography Launch Date1955 |
|||
Diagnostic | Gastrografin Approved UseGastrografin (DIATRIZOIC ACID) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.6 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
102 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
An approach to the performance of contrast studies in contrast material-reactive persons. | 1975 Aug |
|
Transcervical catheterization and cervical patency during the oestrous cycle in domestic cats. | 2001 |
|
Dose reduction in evacuation proctography. | 2001 |
|
Shielding effects of metallic encapsulations and radiographic contrast agents for catheter-based intravascular brachytherapy. | 2001 Apr-Jun |
|
Laparoscopic inflatable band with Roux-en-Y gastric bypass. | 2001 Aug |
|
The role of early radiological studies after gastric bariatric surgery. | 2001 Aug |
|
The use of dilute Calogen as a fat density oral contrast medium in upper abdominal computed tomography, compared with the use of water and positive oral contrast media. | 2001 Aug |
|
An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents. | 2001 Dec |
|
Preoperative bowel preparation with meglumine and sodium diatrizoate (Gastrografin): a prospective randomised comparison. | 2001 Dec |
|
Effects of radiographic contrast media on pulmonary vascular resistance of normoxic and chronically hypoxic pulmonary hypertensive rats. | 2001 Dec |
|
The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. | 2001 Feb 23 |
|
Review of studies establishing the aging male spontaneously hypertensive rat as a detector and quantifier of the kidney toxicity of radiocontrast media and other chemicals. | 2001 Jan |
|
[Nephrotoxicity of X-ray contrast media]. | 2001 Jan-Feb |
|
Glucose alters the susceptibility of mesangial cells to contrast media. | 2001 Jul |
|
Mixed-type hiatal hernia mimicking pulmonary cystic lesion diagnosed by oral urografin in ED. | 2001 Jul |
|
Possibility of sialographic sonography: a Doppler phantom study. | 2001 Jun |
|
Effects in vivo of iohexol and diatrizoate on human plasma acetyl- and butyryl-cholinesterase activity. | 2001 Mar |
|
Dextran sedimentation in a semi-closed system for the clinical banking of umbilical cord blood. | 2001 Mar |
|
BaSO4-loaded agarose: a construction material for multimodality imaging phantoms. | 2001 May |
|
Excretory urography by intraosseous injection of contrast media in a rabbit model. | 2001 May-Jun |
|
Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. | 2001 Nov |
|
Effect of ionic and nonionic contrast media on fibrinolysis in patients undergoing angiocardiography. | 2001 Oct |
|
Oesophageal rupture resulting from airbag deployment during a motor vehicle accident. | 2001 Sep |
|
Ionic radiocontrast media disrupt intercellular contacts via an extracellular calcium-independent mechanism. | 2002 |
|
Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. | 2002 Apr |
|
Diagnosis and management of enterovesical fistulas in patients with Crohn's disease. | 2002 Aug |
|
Electrocardiographic effects of diagnostic imaging agents. | 2002 Aug |
|
Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. | 2002 Aug |
|
Application of oral contrast media in coregistered positron emission tomography-CT. | 2002 Aug |
|
The utility of contrast studies and drains in the management of patients after Roux-en-Y gastric bypass. | 2002 Feb |
|
Plasma exogenous creatinine clearance test in dogs: comparison with other methods and proposed limited sampling strategy. | 2002 Jan-Feb |
|
Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease. | 2002 Jul |
|
Contrast radiography and intestinal obstruction. | 2002 Jul |
|
Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. | 2002 Jul |
|
Type IV diaphragmatic hiatal hernia. | 2002 Jun-Jul |
|
Early esophageal transit study after laparoscopic fundoplication: how useful is it? | 2002 Mar |
|
Role of NO in endothelin-regulated drug transport in the renal proximal tubule. | 2002 Mar |
|
Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis? | 2002 Mar 1 |
|
[Ultrasound and X-ray urethrography and urethroscopy during endoscopic operations on the urethra]. | 2002 Mar-Apr |
|
A case of gastric duplication evaluated by gastric emptying scintigraphy. | 2002 May |
|
Ex vivo expansion of megakaryocyte progenitors from cryopreserved umbilical cord blood. A potential source of megakaryocytes for transplantation. | 2002 Sep |
|
Is same-day sonography of the gallbladder feasible after intravenous urography or contrast-enhanced computed tomography? | 2002 Sep |
|
Iothalamate measured by capillary electrophoresis is a suitable alternative to radiolabeled inulin in renal micropuncture. | 2002 Sep |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: For radiographic examination of segments of the gastrointestinal tract (Gastrografin) oral administration: adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For Enemas or Enterostomy Instillations: should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. http://www.drugs.com/pro/gastrografin.html
;
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C390
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
||
|
CFR |
21 CFR 522.563
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Diatrizoate
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
23672589
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
3321
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
V5403H8VG7
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
m4263
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID7022912
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
DBSALT000267
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
737-31-5
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
212-004-1
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
SUB10547MIG
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
61815
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
DIATRIZOATE SODIUM
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | Description: A white powder; odourless or almost odourless. Solubility: Freely soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Radiocontrast medium. Storage: Sodium amidotrizoate should be kept in a well-closed container, protected from light. Requirements: Sodium amidotrizoate contains not less than 98.0% and not more than the equivalent of 102.0% of C11H8I3N2NaO4, calculated with reference to the anhydrous substance. | ||
|
V5403H8VG7
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
100000091989
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201220
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
C47981
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
8078
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
358
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
53692
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
PRIMARY | |||
|
24360-64-3
Created by
admin on Sat Dec 16 17:55:08 GMT 2023 , Edited by admin on Sat Dec 16 17:55:08 GMT 2023
|
ALTERNATIVE |
ACTIVE MOIETY
SUBSTANCE RECORD